Clinic
Raypar INC
Raypar INC was paid $6.33M by Medicaid between Jan 2018 and Dec 2024, across 32 billing codes. Its largest line is S9083, Global fee urgent care centers — 51% of everything it billed.
33Billing provider infoRAYPAR INC
LAKELAND, FL 33803
LAKELAND, FL 33803
33aNPI1720013337assigned 07/11/2006
33bProvider typeUrgent Care Clinic/Center
28Total paid$6.33M
24GClaims177,081
24DCodes billed32
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Florida
Rank by total paid#7 of 115
Median peer was paid$106K
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24 | $2K | |
| 2019 | 32,277 | $1.14M | |
| 2020 | 16,116 | $867K | |
| 2021 | 26,455 | $1.11M | |
| 2022 | 49,169 | $924K | |
| 2023 | 39,339 | $1.47M | |
| 2024incomplete | 13,701 | $820K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| S9083 | Global fee urgent care centers | 51% | 67,623 | 39,475 | $3.22M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 52,297 | 45,935 | $1.48M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 14% | 14,284 | 12,839 | $877K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.0% | 9,069 | 8,422 | $446K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.5% | 1,633 | 1,533 | $156K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,098 | 10,441 | $59K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,623 | 2,276 | $49K |
| 90473 | <1% | 3,385 | 3,013 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,477 | 1,306 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 855 | 816 | $4K |
| 81025 | <1% | 1,515 | 1,416 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 158 | 155 | $3K |
20 more codes
| 81003 | <1% | 3,109 | $3K | |
| 81002 | <1% | 1,180 | $870.62 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $844.71 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18 | $646.39 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 446 | $352.75 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 111 | $145.86 |
| 87807 | <1% | 17 | $128.70 | |
| H0033 | Oral medication administration, direct observation | <1% | 91 | $120.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 569 | $116.69 |
| 81001 | <1% | 50 | $82.46 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 28 | $20.91 |
| A9150 | Non-prescription drugs | <1% | 4,685 | $4.35 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 269 | $0.07 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 164 | $0.04 |
| 73610 | 0% | 15 | $0.00 | |
| A6448 | Light compression bandage, elastic, knitted/woven, width less than three inches, per yard | 0% | 169 | $0.00 |
| A4570 | Splint | 0% | 15 | $0.00 |
| 99000 | 0% | 20 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 67 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAY, DOROTHY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Raypar INC | Lakeland, FL | $367K |
| Raypar INC | Lakeland, FL | $161K |
| Raypar INC | Winter Haven, FL | $244.56 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.